INTRODUCTION {#s1}
============

Gastric cancer remains the major cause of cancer-related death with a bad prognosis \[[@R1]--[@R3]\]. Despite recent efforts in multimodal treatment approaches, approximately half of patients diagnosed with advanced gastric cancer still die from recurrent disease after surgical resection or distant metastasis \[[@R4], [@R5]\]. Now it has been recognized that multiple genetic and epigenetic alterations or abnormality occur in the development of GC \[[@R6]\]. Thus, the identification on the mechanism of initiation, progression, as well as investigation of differential diagnostic prognostic marker and potential drug target, is still needed and will help to provide better prognosis and individualized treatments.

The sirtuins are a family of proteins homologous to yeast silent information regulator 2 (Sir2) and widely expressed in normal tissues in mammary animals. Up to now, seven members have been identified in human (SIRT1--7) and possess nicotinamide adenine dinucleotide (NAD+)-dependent lysine deacetylase (SIRT1, SIRT2, SIRT3, SIRT5, SIRT6, and SIRT7) and mono-ribosyltransferase (SIRT4 and SIRT6) activities \[[@R7]--[@R14]\]. Recently, SIRT5 was shown to be a NAD+-dependent protein lysine demalonylase and desuccinylase \[[@R15]\]. The sirtuins play essential roles in cellular physiology including cell metabolism, cell cycle, cell division, and transcriptional regulation and are also involved in the pathogenesis of series of diseases such as metabolic diseases \[[@R16]\], neurodegenerative diseases \[[@R17]\], cardiovascular diseases \[[@R18]\], and aging \[[@R19]\]. Some previous studies have been performed to explore the clinical value and mechanism of sirtuins in gastric cancer. However, the results are inconsistent and not all the seven sirtuins are investigated and compared.

Kaplan-Meier plotter (KM plotter), an online tool, can be utilized to analyze correlations of individual genes with prognosis of patients. This database was initially established using data from a group of 1,809 breast cancer patients \[[@R20], [@R21]\]. Later, this database also included gene expression data of a total of 1,065 gastric cancer patients derived from NCBI GEO datasets GSE14210, GSE15459, GSE22377, GSE29272, GSE51105, and GSE62254. In this study, we used datasets GSE15459 and GSE62254 to explore the associations of sirtuins with clinicopathological parameters and used KM plotter database to determine the prognostic role of individual sirtuins in human gastric cancer.

RESULTS {#s2}
=======

Correlations of sirtuins with clinicopathological parameters in GC {#s2_1}
------------------------------------------------------------------

The associations of sirtuins with the clinicopathological parameters of the patients with GC were firstly explored. We downloaded the datasets, GSE62254 and GSE15459, from NCBI GEO database. Both datasets were consisted of relative large cohort of GC patients and have also been included in the KM plotter database. In GSE62254, SIRT1 and SIRT2 exerted no associations with the clinical features, SIRT3 was associated with T stage, SIRT4 was associated with pStage, SIRT5 was associated with T stage, SIRT6 was associated with age, M stage, and pStage, and SIRT7 was associated with Lauren classification, N stage, and pStage (Table [1](#T1){ref-type="table"}). In GSE15459, significant associations were found between Lauren classification and SIRT7, pStage and SIRT2, and pStage and SIRT3 (Table [2](#T2){ref-type="table"}). In addition, GSE62254 and GSE15459 were also integrated to investigate the correlations of sirtuins with clinicopathological parameters in GC. The results suggested SIRT4, SIRT6, and SIRT7 were associated with Lauren classification, and SIRT3-5 were associated with pStage (Table [3](#T3){ref-type="table"}). Meanwhile, the KM plotter database also included gene expression profile of normal/adjacent tissue from 57 cases. Compare with the normal/adjacent tissues, SIRT2-6 expression in GC cancer tissues was lower while SIRT1 and SIRT7 had no difference ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). However, the controls were rare and not each separate dataset was consisted of controls, and the results should further verified.

###### Sirtuins and clinicopathological parameters in patients with GC (GSE62254)

  Parameters                  Cases   SIRT1+   SIRT2+   SIRT3+   SIRT4+   SIRT5+   SIRT6+   SIRT7+
  --------------------------- ------- -------- -------- -------- -------- -------- -------- --------
  **Gender**                                                                                
  Male                        199     98       96       102      93       98       93       101
  Female                      101     52       54       48       57       52       57       49
  Age                                                                                       
  \< 65                       161     78       82       78       87       79       70\*     81
  ≥ 65                        139     72       68       72       63       71       80       61
  **Lauren classification**                                                                 
  Intestinal                  150     75       75       85       69       82       83       85\*
  Diffuse                     142     71       72       62       78       64       62       64
  Mixed                       8       4        3        3        3        4        5        1
  **T stage**                                                                               
  2                           188     88       93       105\*    93       104\*    100      102
  3                           91      49       47       34       50       36       38       37
  4                           21      13       10       11       7        10       12       11
  **N stage**                                                                               
  0                           38      20       19       18       16       19       24       10\*
  1                           131     58       60       63       72       71       65       75
  2                           80      46       43       44       42       42       33       42
  3                           51      26       28       25       20       18       28       23
  **M stage**                                                                               
  0                           273     139      133      138      139      137      143\*    133
  1                           27      11       17       12       11       13       7        17
  **pStage**                                                                                
  1                           30      14       14       17       11\*     15       22\*     8\*
  2                           97      42       46       50       56       55       49       57
  3                           96      53       49       47       52       49       42       47
  4                           77      41       41       36       77       31       37       38

\**P* \< 0.05 demonstrated by Chi-square test.

###### Sirtuins and clinicopathological parameters in patients with GC (GSE15459)

  Parameter                   Cases   SIRT1+   SIRT2+   SIRT3+   SIRT4+   SIRT5+   SIRT6+   SIRT7+
  --------------------------- ------- -------- -------- -------- -------- -------- -------- --------
  **Gender**                                                                                
  Male                        125     63       67       65       66       59       66       63
  Female                      67      33       29       31       30       37       30       33
  **Age**                                                                                   
  \< 65                       84      42       38       47       40       41       45       42
  ≥ 65                        108     54       58       49       56       55       51       54
  **Lauren classification**                                                                 
  Intestinal                  99      43       49       43       50       49       54       60\*
  Diffuse                     75      42       39       45       41       38       33       28
  Mixed                       18      11       8        8        5        9        9        8
  **pStage**                                                                                
  1                           31      17       24\*     22\*     17       19       15       17
  2                           29      17       15       15       16       19       15       13
  3                           72      32       31       39       30       35       39       38
  4                           60      30       26       20       33       23       27       28

\**P* \< 0.05 demonstrated by Chi-square test.

###### Sirtuins and clinicopathological parameters in patients with GC (integrated analysis of GSE62254 and GSE15459)

  Parameters                  Cases   SIRT1+   SIRT2+   SIRT3+   SIRT4+   SIRT5+   SIRT6+   SIRT7+
  --------------------------- ------- -------- -------- -------- -------- -------- -------- --------
  **Gender**                                                                                
  Male                        324     161      163      167      159      157      159      164
  Female                      168     85       83       79       87       89       87       82
  **Age**                                                                                   
  \< 65                       245     120      120      125      127      120      115      123
  ≥ 65                        247     126      126      121      119      126      131      115
  **Lauren classification**                                                                 
  Intestinal                  249     118      124      128      119\*    131      137\*    145\*
  Diffuse                     217     113      111      107      119      102      95       92
  Mixed                       26      15       11       11       8        13       14       9
  **pStage**                                                                                
  1                           61      31       38       39\*     28\*     34\*     37       25
  2                           126     59       61       65       72       74       64       70
  3                           168     85       80       86       82       84       81       85
  4                           137     71       67       56       110      54       64       66

\**P* \< 0.05 demonstrated by Chi-square test.

Correlations of sirtuins with OS in GC in overall {#s2_2}
-------------------------------------------------

In overall, 876 GC cases in KM plotter database were available to investigate the correlations of SIRT1-4 and SIRT6-7 with OS while 631 cases were available for SIRT1. Auto select best cutoff value was used to split the patients in survival analyses. Survival curves suggested that high expression of SIRT1 mRNA was favorable for OS (SIRT1: HR = 0.64, 95% CI = 0.54--0.76, *P* = 2.2E-07), high expressions of SIRT2-4 and SIRT6-7 were poor for OS (SIRT2: HR = 2.31, 95% CI = 1.87--2.87, *P* = 3.6E-15; SIRT3: HR = 1.99, 95% CI = 1.62--2.45, *P* = 2.6E-11; SIRT4: HR = 1.41, 95% CI = 1.19--1.68, *P* = 6.6E-05; SIRT6: HR = 2.02, 95% CI = 1.66--2.47, *P* = 1.7E-12; SIRT7: HR = 1.96, 95% CI = 1.63--2.35, *P* = 2.7E-13), and no significant association existed between SIRT5 and OS in GC (Figure [1](#F1){ref-type="fig"} and Table [4](#T4){ref-type="table"}).
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(**A**) SIRT1 (*n* = 876). (**B**) SIRT2 (*n* = 876). (**C**) SIRT3 (*n* = 876). (**D**) SIRT4 (*n* = 876). (**E**) SIRT5 (*n* = 631). (**F**) SIRT6 (*n* = 836). (**G**) SIRT7 (*n* = 836).](oncotarget-08-74359-g001){#F1}

###### Correlations of sirtuins with OS in GC in overall

  Sirtuins   Cases   HR         95% CI           *P*-value
  ---------- ------- ---------- ---------------- -------------
  SIRT1      876     **0.64**   **0.54--0.76**   **2.2E-07**
  SIRT2      876     **2.31**   **1.87--2.87**   **3.6E-15**
  SIRT3      876     **1.99**   **1.62--2.45**   **2.6E-11**
  SIRT4      876     **1.41**   **1.19--1.68**   **6.6E-05**
  SIRT5      631     1.14       0.92--1.42       2.3E-01
  SIRT6      876     **2.02**   **1.66--2.47**   **1.7E-12**
  SIRT7      876     **1.96**   **1.63--2.35**   **2.7E-13**

Then we performed subgroup analyses to explore the effects of clinicopathological features, such as gender, stage, Lauren classification, differentiation, treatment, and HER2 status, on the associations between sirtuins mRNA expression and OS in GC. The effects of gender were firstly investigated. There were 545 male GC patients available for analyzing the correlations between SIRT1-4 and 6-7 and OS while there were 349 male GC patients available for SIRT5. And 236 female patients were available for SIRT1-4 and 6-7 and 187 female patients for SIRT5. Either in male patients or female patients, SIRT1-4 and SIRT6-7 were associated with OS while SIRT5 was not significantly associated with OS (Table [5](#T5){ref-type="table"}).

###### Correlations of sirtuins with OS in GC stratified by gender

  Sirtuins   Gender   Cases   HR         95% CI           *P*-value
  ---------- -------- ------- ---------- ---------------- -------------
  SIRT1      Male     545     **0.45**   **0.31--0.66**   **1.7E-05**
             Female   236     **0.63**   **0.51--0.77**   **1.3E-05**
  SIRT2      Male     545     **2.08**   **1.38--3.14**   **3.5E-04**
             Female   236     **2.62**   **2.02--3.40**   **6.2E-14**
  SIRT3      Male     545     **2.12**   **1.41--3.18**   **2.1E-04**
             Female   236     **2.07**   **1.60--2.67**   **1.8E-08**
  SIRT4      Male     545     **1.88**   **1.33--2.68**   **3.3E-04**
             Female   236     **1.46**   **1.16--1.84**   **1.4E-03**
  SIRT5      Male     349     0.76       0.48--1.20       2.3E-01
             Female   187     0.80       0.57--1.12       2.0E-01
  SIRT6      Male     545     **2.24**   **1.41--3.55**   **4.4E-04**
             Female   236     **2.26**   **1.75--2.92**   **1.6E-10**
  SIRT7      Male     545     **1.96**   **1.38--2.79**   **1.2E-04**
             Female   236     **2.12**   **1.68--2.67**   **6.6E-11**

Secondly, subgroup analyses according to stage were performed. In patients with stage 1 cancer, significant association was only found between SIRT2 and OS (*n* = 67, Table [6](#T6){ref-type="table"}). In stage 2, SIRT2, 3, 4, 6, and 7 were correlated with OS (*n* = 140). In stage 3, all sirtuins were correlated with OS (*n* = 305 for SIRT1-4 and 6-7, *n* = 197 for SIRT5). And in stage 4, significant association was identified between SIRT2, 5, 6, and 7 and OS (*n* = 140). Notably, unlike the results in overall, SIRT5 was significantly associated with OS in stage 3 and stage 4, however, exerting opposite effects on OS (stage 3, n=197, HR=1.70, 95% CI = 1.16--2.49, *P* = 6.3E-03; stage 4, *n* = 140, HR = 0.63, 95% CI = 0.42--0.94, *P* = 2.2E-02).

###### Correlations of sirtuins with OS in GC stratified by stages

  Sirtuins   Stage   Cases   HR          95% CI            *P*-value
  ---------- ------- ------- ----------- ----------------- -------------
  SIRT1      1       67      0.38        0.14--1.06        5.6E-02
             2       140     1.55        0.78--3.06        2.1E-01
             3       305     **0.59**    **0.43--0.81**    **9.4E-04**
             4       148     0.81        0.55--1.19        2.8E-01
  SIRT2      1       67      **4.71**    **1.33--16.74**   **8.5E-03**
             2       140     **2.55**    **1.37--4.76**    **2.3E-03**
             3       305     **2.60**    **1.79--3.77**    **2.1E-07**
             4       148     **1.65**    **1.11--2.46**    **1.3E-02**
  SIRT3      1       67      **11.02**   **1.44--84.40**   **3.9E-03**
             2       140     **3.36**    **1.69--6.70**    **2.5E-04**
             3       305     **2.21**    **1.52--3.21**    **1.8E-05**
             4       148     0.76        0.50--1.14        1.8E-01
  SIRT4      1       67      1.88        0.70--5.08        2.1E-01
             2       140     **2.25**    **1.22--4.18**    **8.1E-03**
             3       305     **1.43**    **1.08--1.90**    **1.3E-02**
             4       148     1.32        0.89--1.97        1.6E-01
  SIRT5      1       62      3.00        0.66--13.58       1.3E-01
             2       135     1.91        0.91--4.03        8.1E-02
             3       197     **1.70**    **1.16--2.49**    **6.3E-03**
             4       140     **0.63**    **0.42--0.94**    **2.1E-02**
  SIRT6      1       67      2.63        0.083--8.29       8.7E-02
             2       140     **2.69**    **1.42--5.12**    **1.7E-03**
             3       305     **1.90**    **1.42--2.54**    **1.0E-05**
             4       148     **1.49**    **1.02--2.2**     **3.9E-02**
  SIRT7      1       67      2.76        0.94--8.08        5.4E-02
             2       140     **2.03**    **1.11--3.72**    **1.9E-02**
             3       305     **1.81**    **1.33--2.46**    **1.3E-04**
             4       148     **1.60**    **1.05--2.45**    **2.8E-02**

Thirdly, Lauren classification was used to stratify the patients. SIRT1, 2, 3, 6, and 7 were found to be associated with OS in intestinal GC (*n* = 320, Table [7](#T7){ref-type="table"}). SIRT2, 3, and 4 were associated with OS in diffuse GC (*n* = 141). And, only SIRT3 was associated with OS in mixed GC (*n* = 32).

###### Correlations of sirtuins with OS in GC stratified by lauren classification

  Sirtuins   Lauren classification   Cases   HR         95% CI            *P*-value
  ---------- ----------------------- ------- ---------- ----------------- -------------
  SIRT1      Intestinal              320     **0.51**   **0.37--0.70**    **2.1E-05**
             Diffuse                 141     1.26       0.88--1.81        2.1E-01
             Mixed                   32      0.43       0.15--1.22        1.0E-01
  SIRT2      Intestinal              320     **3.39**   **2.32--4.95**    **2.4E-11**
             Diffuse                 141     **1.71**   **1.17--2.51**    **5.4E-03**
             Mixed                   32      2.02       0.57--7.23        2.7E-01
  SIRT3      Intestinal              320     **2.74**   **1.89--3.96**    **2.4E-08**
             Diffuse                 141     **1.44**   **1.01--2.04**    **4.3E-02**
             Mixed                   32      **4.07**   **1.14--14.47**   **1.9E-02**
  SIRT4      Intestinal              320     **1.37**   **1.00--1.88**    **4.8E-02**
             Diffuse                 141     **1.59**   **1.13--2.24**    **7.1E-03**
             Mixed                   32      2.42       0.86--6.85        8.6E-02
  SIRT5      Intestinal              169     1.32       0.90--1.93        1.5E-01
             Diffuse                 140     0.79       0.56--1.12        1.8E-01
             Mixed                   29      0.37       0.11--1.20        8.4E-02
  SIRT6      Intestinal              320     **3.03**   **2.05--4.48**    **4.9E-09**
             Diffuse                 141     1.38       0.98--1.95        6.8E-02
             Mixed                   32      2.31       0.77--6.94        1.2E-01
  SIRT7      Intestinal              320     **2.71**   **1.91--3.83**    **5.1E-09**
             Diffuse                 141     1.37       0.97--1.92        7.1E-02
             Mixed                   32      2.40       0.83--6.95        9.7E-02

Furthermore, subgroup analyses according to differentiation or treatment were also performed, respectively. In GC with poor differentiation, significant associations were identified between SIRT4-5 and OS (*n* = 165 for SIRT4; *n* = 121 for SIRT5, Table [8](#T8){ref-type="table"}). And significant association was only found between SIRT3 and OS in GC with moderated differentiation (*n* = 67). In GC with well differentiation, SIRT3 and 7 was associated with OS (*n* = 32). For association between SIRT5 and OS in GC with well differentiation, analysis could not be conducted due to the case number was very small (*n* = 5). After grouping by treatment (surgery alone, 5-FU adjuvant therapy, or other adjuvant therapy), significant associations were found between SIRT2-4 and OS in GC patients underwent surgery alone (*n* = 380, Table [9](#T9){ref-type="table"}). In patients underwent 5-FU adjuvant therapy, significant associations were found between SIRT1, 2, 5, and 7 and OS (*n* = 153, Table [9](#T9){ref-type="table"}). And significant associations were found between SIRT6 and OS in patients underwent other adjuvant therapy (*n* = 76, Table [9](#T9){ref-type="table"}).

###### Correlations of sirtuins with OS in GC stratified by differentiation

  Sirtuins   Differentiation   Cases   HR         95% CI           P-value
  ---------- ----------------- ------- ---------- ---------------- -------------
  SIRT1      Poor              165     0.71       0.46--1.10       1.2E-01
             Moderate          67      0.62       0.32--1.21       1.6E-01
             Well              32      0.50       0.19--1.30       1.5E-01
  SIRT2      Poor              165     0.72       0.48--1.10       1.3E-01
             Moderate          67      1.43       0.72--2.83       3.1E-01
             Well              32      0.44       0.15--1.31       1.3E-01
  SIRT3      Poor              165     1.24       0.83--1.85       2.9E-01
             Moderate          67      **0.47**   **0.25--0.90**   **2.0E-02**
             Well              32      **3.89**   **1.59--9.49**   **1.5E-03**
  SIRT4      Poor              165     **1.79**   **1.19--2.68**   **4.2E-03**
             Moderate          67      0.56       0.27--1.14       1.0E-01
             Well              32      0.45       0.18--1.15       8.8E-02
  SIRT5      Poor              121     **0.57**   **0.35--0.93**   **2.1E-02**
             Moderate          67      1.42       0.72--2.81       3.1E-01
             Well              5       NA                          
  SIRT6      Poor              165     0.75       0.49--1.12       1.6E-01
             Moderate          67      1.75       0.9--3.42        9.5E-02
             Well              32      0.62       0.25--1.55       3.1E-01
  SIRT7      Poor              165     1.37       0.88--2.12       1.6E-01
             Moderate          67      1.61       0.67--3.88       2.8E-01
             Well              32      **0.30**   **0.10--0.90**   **2.3E-02**

###### Correlations of sirtuins with OS in GC stratified by treatment

  Sirtuins   Treatment        Cases   HR         95% CI           *P*-value
  ---------- ---------------- ------- ---------- ---------------- -------------
  SIRT1      Surgery alone    380     1.20       0.89--1.62       2.4E-01
             5-FU adjuvant    153     **0.64**   **0.44--0.95**   **2.4E-02**
             Other adjuvant   76      1.99       0.72--5.47       1.8E-01
  SIRT2      Surgery alone    380     **1.55**   **1.15--2.08**   **3.7E-03**
             5-FU adjuvant    153     **0.68**   **0.48--0.96**   **2.8E-02**
             Other adjuvant   76      6.10       1.41--26.33      5.7E-03
  SIRT3      Surgery alone    380     **1.47**   **1.09--1.97**   **1.1E-02**
             5-FU adjuvant    153     0.71       0.48--1.05       8.3E-02
             Other adjuvant   76      1.66       0.68--4.05       2.6E-01
  SIRT4      Surgery alone    380     **1.37**   **1.02--1.82**   **3.3E-02**
             5-FU adjuvant    153     1.25       0.85--1.84       2.5E-01
             Other adjuvant   76      0.60       0.22--1.66       3.2E-01
  SIRT5      Surgery alone    380     1.26       0.94--1.69       1.2E-01
             5-FU adjuvant    34      0.23       0.08--0.68       3.7E-03
             Other adjuvant   76      0.75       0.31--1.80       5.1E-01
  SIRT6      Surgery alone    380     1.33       1.00--1.79       5.2E-02
             5-FU adjuvant    153     1.26       0.89--1.79       1.9E-01
             Other adjuvant   76      **0.36**   **0.15--0.88**   **2.0E-02**
  SIRT7      Surgery alone    380     **1.35**   **1.01--1.80**   **4.3E-02**
             5-FU adjuvant    153     **1.60**   **1.12--2.27**   **8.4E-03**
             Other adjuvant   76      0.59       0.24--1.43       2.4E-01

Finally, effects of HER2 status on the associations between sirtuins and OS in GC were evaluated. In GC with negative HER2 status, all sirtuins except SIRT5 and SIRT7 were associated with OS (*n* = 532, Table [10](#T10){ref-type="table"}) and in GC with positive HER2 status, all sirtuins except SIRT4 were associated with OS (*n* = 344 for SIRT1-4 and 6-7; *n* = 202 for SIRT5).

###### Correlations of sirtuins with OS in GC stratified by HER2 status

  Sirtuins   HER2 status   Cases   HR         95% CI           *P*-value
  ---------- ------------- ------- ---------- ---------------- -------------
  SIRT1      Negative      532     **0.64**   **0.51--0.81**   **1.4E-04**
             Positive      344     **0.58**   **0.42--0.80**   **7.3E-04**
  SIRT2      Negative      532     **2.20**   **1.71--2.83**   **3.9E-10**
             Positive      344     **1.58**   **1.14--2.18**   **5.5E-03**
  SIRT3      Negative      532     **1.68**   **1.31--2.15**   **3.2E-05**
             Positive      344     **1.52**   **1.11--2.06**   **7.7E-03**
  SIRT4      Negative      532     **1.60**   **1.27--2.00**   **4.7E-05**
             Positive      344     1.28       0.98--1.67       7.0E-02
  SIRT5      Negative      429     0.83       0.62--1.12       2.2E-01
             Positive      202     0.63       **0.43--0.94**   **2.2E-02**
  SIRT6      Negative      532     1.81       **1.43--2.29**   **5.2E-07**
             Positive      344     1.76       **1.28--2.41**   **3.8E-04**
  SIRT7      Negative      532     1.91       **1.53--2.40**   **1.0E-08**
             Positive      344     1.60       **1.23--2.07**   **3.8E-04**

In addition, the online database also included the first progression (FP) information of the GC patients, and the analyses results suggested that high expression of SIRT1 was associated with long FP time while high expression of SIRT2-4 and SIRT6-7 was associated with short FP time and no significant association was found between SIRT5 and FP in GC in overall ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s3}
==========

Gastric cancer (GC) is main cause of cancer related death and presents high mortality rate among all digestive tract malignancies due to chemoradiotherapy resistance and distant metastasis. Thus it is crucial to reveal pathogenesis of GC and find novel prognostic strategies, early diagnostic tools, and effective therapeutic approaches. Here, we used an online database to explore the clinical value of sirtuins in predicting overall survival (OS) in GC.

Of all the seven sirtuins, SIRT1 was the most studied one in GC. A series of studies have investigated the associations of SIRT1 with OS in GC. Of which, four studies reported that high SIRT1 expression was associated with poor OS \[[@R22]--[@R25]\] while one study reported that there was a trend of association between SIRT1 with good OS \[[@R26]\]. A meta-analysis combing the previous studies suggested that high SIRT1 expression was closely linked with the 3-year OS (OR = 0.25, 95% CI = 0.16--0.39, *P* \< 0.00001, fixed model) while it was not associated with 5-year OS (OR = 0.44, 95% CI = 0.15--1.28, *P* = 0.13, random model) \[[@R27]\]. In our study, we found that high expression of SIRT1 mRNA was favorable for OS (SIRT1: HR = 0.64, 95% CI = 0.54--0.76, *P* = 2.2E-07). The inconsistency of these results might be due to the heterogeneity of these studies such as sample size, cancer site, and cutoff value. Several meta-analyses have also been performed to evaluate the associations of SIRT1 with OS in other solid carcinomas. All the meta-analyses studies revealed a significant association between high SIRT1 with poor OS in these solid carcinomas including breast cancer \[[@R28]\], hepatocellular carcinoma \[[@R29]\], colorectal cancer \[[@R30]\], lung cancer \[[@R31], [@R32]\], liver cancer \[[@R32]\]. Wang et al. also have pooled all the eligible data of solid malignancies and identified the same conclusion \[[@R32]\]. Mechanism researches suggested that SIRT1 can counteract the activation of STAT3 and NF-κB to repress cell growth \[[@R33]\] and lead to G1-phase arrest via NF-κB/Cyclin D1 signaling in gastric cancer\[[@R34]\]. The previous studies suggested that SIRT1 was also the target of certain microRNAs such as miR-543 and miR-204. miR-543 can promote gastric cancer cell proliferation by targeting SIRT1\[[@R35]\] and miR-204 can down-regulate SIRT1 and revert SIRT1-induced epithelial-mesenchymal transition, anoikis resistance, and invasion in gastric cancer\[[@R36]\].

For SIRT2, a previous study indicated that combination of SIRT2 with other three genes could be used to predict OS in GC\[[@R37]\]. Here, we identified that high expression of SIRT2 expression was a biomarker of worse OS in GC patients (HR = 2.31, 95% CI = 1.87--2.87, *P* = 3.6E-15).

Up to now, there were three studies reporting the association of SIRT3 with OS in GC. The association was significant in two studies \[[@R38], [@R39]\] and insignificant in one study \[[@R40]\]. A meta-analysis has pooled the previous two studies and found increased SIRT3 expression was associated with better OS in GC, however, the total included cases were only 286 \[[@R41]\]. Our results suggested that high SIRT3 mRNA expression was associated with poor prognosis in GC (HR = 1.99, 95% CI = 1.62--2.45, *P* = 2.6E-11). The inconsistency needed to be verified in further studies with large scale of patients. Function studies revealed that SIRT3 plays dual role in GC development. Wang et al. reported that SIRT3 can inhibit cell proliferation in human gastric cancer through down-regulation of Notch-1 \[[@R42]\] whereas Cui et al. reported that SIRT3 can enhance glycolysis and proliferation in SIRT3-expressing GC Cells \[[@R43]\].

The study performed by Huang et al. suggested SIRT4 is associated with some clinicopathological features in GC but did not reported the association of SIRT4 with prognosis \[[@R44]\]. In the present study, we found that high SIRT4 mRNA expression exhibited a significant associations with Lauren classification, pStage, and OS in GC (OS: HR = 1.41, 95% CI = 1.19--1.68, *P* = 6.6E-05).

Currently, SIRT5 and 6 have not been investigated in gastric cancer, but have been shown to be involved in other cancers, such as breast cancer, lung cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, and ovarian cancer \[[@R45]--[@R50]\]. Our study revealed that high SIRT6 expression was associated with poor OS in GC (HR = 2.02, 95% CI = 1.66--2.47, *P* = 1.7E-12) while SIRT5 was not correlated with OS (HR=1.14, 95% CI=0.92--1.42, *P* = 0.23). Interestingly, after stratification by stage or differentiation, high SIRT5 mRNA expression was associated with OS in stage 3 (HR=1.70, 95% CI = 1.16--2.49, *P* = 6.3E-03), stage 4 (HR = 0.63, 95% CI = 0.42--0.94), and poor differentiated GC (HR = 0.57, 95% CI = 0.35--0.93, *P* = 2.1E-02). The different effects of SIRT5 on OS in GC with different stages or differentiations should be checked in more large cohorts.

Involvement of SIRT7 in GC was reported in only one study that it can promote gastric cancer growth and inhibit apoptosis by epigenetically inhibiting miR-34a and is associated with poor prognosis \[[@R51]\]. Here, we also identified SIRT7 as a biomarker for poor OS in GC (HR = 1.73, 95% CI = 1.45--2.05, *P* = 3.2E-10).

MATERIALS AND METHODS {#s4}
=====================

To investigate the associations of sirtuins mRNA levels with clinicopathological parameters, we downloaded gastric cancer mRNA profile data and corresponding clinical data from publicly available GEO database. GSE62254 and GSE15459 with large number of gastric cancer patient samples and complete clinical information were selected, which had been also included in the Kaplan-Meier plotter database. The clinical samples were stratified into two groups by sirtuins mRNA levels with the median as cut-off value. The Chi-square test or Fisher's exact test were performed to explore the correlations between sirtuins expression and clinicopathological parameters. Statistical analyses were conducted with the software GraphPad Prism 6. *P* value less than 0.05 was considered statistically significant.

Then we used the Kaplan-Meier plotter ([www.kmplot.com](http://www.kmplot.com)) to investigate the predictive value of mRNA expressions of sirtuins in overall survival in gastric cancer. Currently, the Kaplan-Meier plotter is capable to assess the effect of 54, 675 genes on survival of 10, 188 clinical cancer samples, including 4, 142 breast, 1, 648 ovarian, 2, 437 lung and 1, 065 gastric cancer patients\[[@R52]\]. Briefly, the seven sirtuins (SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7) were entered into the database (<http://kmplot.com/analysis/index>. php?p = service and cancer = gastric) to obtain Kaplan-Meier plots in which the number-at-risk is indicated below the main plot. The Affy IDs of SIRT1-7 were 218878_s\_at (SIRT1), 220605_s\_at (SIRT2), 221913_at (SIRT3), 220047_at (SIRT4), 229112_at (SIRT5), 219613_s\_at (SIRT6), and 218797_s\_at (SIRT7), respectively. If the gene had multiple chip probe sets, JetSet best probe set was selected. The patient samples were divided into two groups according to the mRNA expression with auto select best cutoff value (high vs. low expression). The hazard ratio (HR) with 95% confidence intervals and log rank *p* value was calculated and displayed on the webpage. HER2 status was determined using the gene chip probe set 216836_s\_at as described before \[[@R21]\].

CONCLUSIONS {#s5}
===========

To investigate and compare the clinical value of sirtuins in predicting overall survival in GC, we analyze the associations of all sirtuins (SIRT1-7) mRNA expressions with overall survival in GC using an online database, KM plotter. And the results suggested that high SIRT1 mRNA level was associated with better overall survival, SIRT2-4 and 6-7 were associated with poor overall survival, whereas SIRT5 did not show significant association with overall survival in GC.

SUPPLEMENTARY MATERIALS FIGURE AND TABLES {#s6}
=========================================
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